Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (vol 24, pg 1649, 2018)

被引：11

作者：

Amaria, Rodabe N.

Reddy, Sangeetha M.

Tawbi, Hussein A.

Davies, Michael A.

Ross, Merrick I.

Glitza, Isabella C.

Cormier, Janice N.

Lewis, Carol

Hwu, Wen-Jen

Hanna, Ehab

Diab, Adi

Wong, Michael K.

Royal, Richard

Gross, Neil

Weber, Randal

Lai, Stephen Y.

Ehlers, Richard

Blando, Jorge

Milton, Denai R.

Woodman, Scott

Kageyama, Robin

Wells, Daniel K.

Hwu, Patrick

Patel, Sapna P.

Lucci, Anthony

Hessel, Amy

Lee, Jeffrey E.

Gershenwald, Jeffrey

Simpson, Lauren

Burton, Elizabeth M.

Posada, Liberty

Haydu, Lauren

Wang, Linghua

Zhang, Shaojun

Lazar, Alexander J.

Hudgens, Courtney W.

Gopalakrishnan, Vancheswaran

Reuben, Alexandre

Andrews, Miles C.

Spencer, Christine N.

Prieto, Victor

Sharma, Padmanee

Allison, James

Tetzlaff, Michael T.

Wargo, Jennifer A.

机构：

[1] MD Anderson Cancer Center,Department of Melanoma Medical Oncology

[2] MD Anderson Cancer Center,Department of Breast Medical Oncology

[3] MD Anderson Cancer Center,Department of Surgical Oncology

[4] MD Anderson Cancer Center,Department of Head and Neck Surgery

[5] MD Anderson Cancer Center,Department of Immunology

[6] MD Anderson Cancer Center,Department of Biostatistics

[7] Parker Institute for Cancer Immunotherapy,Department of Genomic Medicine

[8] MD Anderson Cancer Center,Department of Pathology

[9] MD Anderson Cancer Center,Department of Genitourinary Cancers

[10] MD Anderson Cancer Center,Department of Translational and Molecular Pathology

[11] MD Anderson Cancer Center,undefined

来源：

NATURE MEDICINE | 2018年 / 24卷 / 12期

关键词：

D O I：

10.1038/s41591-018-0252-y

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In the version of this article originally published, there was an error in Fig. 1. In the neoadjuvant phase column, the n values for arms A and B were both reported to be 20. The n values for arms A and B were actually 12 and 11, respectively. Also, the URL underlying the accession code in the data availability section was incorrect. The URL was originally https://www.ebi.ac.uk/ega/studies/EGAS00001002698. It should have been https://www.ebi.ac.uk/ega/studies/EGAS00001003178. The errors have been corrected in the print, HTML and PDF versions of this article.

引用

页码：1942 / 1942

页数：1

共 50 条

[31] Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.
Wargo, Jennifer Ann
Amaria, Rodabe Navroze
Ross, Merrick I.
Saw, Robyn P. M.
Gershenwald, Jeffrey E.
Hwu, Patrick
Patel, Sapna Pradyuman
Glitza, Isabella Claudia
Diab, Adi
Kefford, Richard
Scolyer, Richard A.
Rizos, Helen
Thompson, John F.
Shannon, Kerwin
Spillane, Andrew
Carlino, Matteo S.
Guminski, Alex
Simpson, Lauren
Davies, Michael A.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[32] Neoadjuvant combination targeted and immunotherapy for high-risk resectable stage III melanoma (NeoACTIVATE), NCT03554083
Hieken, Tina J.
Suman, Vera J.
Holtan, Shernan G.
Flotte, Thomas J.
Kottschade, Lisa A.
Block, Matthew S.
CANCER RESEARCH, 2019, 79 (13)
[33] Neoadjuvant Therapy for High-Risk Bulky Regional Melanoma
Tarhini, Ahmad A.
Pahuja, Shalu
Kirkwood, John M.
JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (04) : 386 - 390
[34] Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Nierengarten, Mary Beth
CANCER, 2023, 129 (13) : 1952 - 1952
[35] IMMUNOTHERAPY WITH CHECKPOINT BLOCKADE FOR UROTHELIAL CANCER (vol 199, pg 1136, 2018)
Siefker-Radtke, A. O.
Apolo, A. B.
Bivalacqua, T. J.
Spiess, P. E.
Black, P. C.
JOURNAL OF UROLOGY, 2018, 200 (03): : 660 - 660
[36] Microglial immune checkpoint mechanisms (vol 21, pg 779, 2018)
Deczkowska, Aleksandra
Amit, Ido
Schwartz, Michal
NATURE NEUROSCIENCE, 2018, 21 (08) : 1137 - 1137
[37] IMMUNE INFILTRATES ARE ASSOCIATED WITH CLINICAL OUTCOMES IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA (STS) TREATED WITH NEOADJUVANT IMMUNE CHECKPOINT BLOCKADE (ICB)
Keung, Emily
Nassif, Elise
Lin, Heather
Lazar, Alexander
Wang, Wei-Lien
Parra, Edwin
Lima, Cibelle
Wistuba, Ignacio
Guadagnolo, Ashleigh
Bishop, Andrew
Lewis, Valerae
Torres, Keila
Hunt, Kelly
Feig, Barry
Scally, Christopher
Al Rawi, Ahmed
Crosby, Shadarra
Mathew, Grace
Ingram, Davis
Wani, Khalida
Wargo, Jennifer
Somaiah, Neeta
Roland, Christina
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A410 - A412
[38] NEOADJUVANT VIDUTOLIMOD (VIDU) AND NIVOLUMAB (NIVO) RESULTS IN MPR AND IMMUNE ACTIVATION IN HIGH-RISK RESECTABLE MELANOMA (MEL): FINAL PHASE II CLINICAL TRIAL RESULTS
Karunamurthy, Arivarasan
Chauvin, Joe-Marc
Morrison, Robert
Bai, Yulong
Sun, Jie
Wang, Hong
Hartman, Douglas
Stein, Julie
Deitrick, Christopher
Bao, Riyue
Singh, Jagjit
Ding, Quanquan
Gao, Wentao
Hurd, Drew
Pagliano, Ornella
Rose, Amy
Najjar, Yana
Luke, Jason
Mauro, David
Krieg, Arthur
Wooldridge, James
Bobilev, Dmitri
Kirkwood, John
Taube, Janis
Park, Hyun Jung
Zarour, Hassane
Davar, Diwakar
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A634 - A635
[39] Neoadjuvant immune-checkpoint blockade therapy combined with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING)
Tan, Li
Xu, Lixia
Shen, Shun-Li
Li, Dongming
Hua, Yunpeng
Li, Shaoqiang
Liang, Lijian
He, Qiang
Zhou, Qi
Xie, Wenxuan
Chen, Zebin
Wu, Jian
Li, Jiaping
Fan, Wenzhe
Zhuang, Wenquan
Chen, Lili
Feng, Shiting
Peng, Sui
Wang, Jiping
Kuang, Ming
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[40] ADJUVANT AND NEOADJUVANT CHEMOTHERAPY WITH DACARBAZINE IN HIGH-RISK CHILDHOOD MELANOMA
BODDIE, AW
CANGIR, A
CANCER, 1987, 60 (08) : 1720 - 1723

← 1 2 3 4 5 →